ISSN (Print): 2374-1996

ISSN (Online): 2374-2003


Editor-in-chief: Jean Rommelaere

You are here

Currrent Issue: Volume 4, Number 4, 2016


Hepatocellular Carcinoma: A Focus on the New Lines of Management

1Department of Clinical Pharmacy, College of Pharmacy, Taif University, Taif, KSA

2Department of Pharmacology, Faculty of Medicine, Tanta University, Tanta, Egypt

3Final year student, College of Pharmacy, Taif University, Taif, KSA

Journal of Cancer Research and Treatment. 2016, 4(4), 55-60
doi: 10.12691/jcrt-4-4-1
Copyright © 2016 Science and Education Publishing

Cite this paper:
Ahmed M. Kabel, Abrar A. Al-joaid, Afnan A. Al-ghamdi, Aseel A. Al-joaid, Wejdan S. Al-zaidi. Hepatocellular Carcinoma: A Focus on the New Lines of Management. Journal of Cancer Research and Treatment. 2016; 4(4):55-60. doi: 10.12691/jcrt-4-4-1.

Correspondence to: Ahmed  M. Kabel, Department of Clinical Pharmacy, College of Pharmacy, Taif University, Taif, KSA. Email:


Hepatocellular carcinomas (HCCs) are aggressive tumors with a high dissemination rate. Diagnosis of HCC depends on physical examination, computed tomography, magnetic resonance imaging and biopsy results. An early diagnosis of these tumors is of great importance in order to offer the possibility of curative treatment. HCC is relatively insensitive to systemic therapy, radiotherapy or surgery and this usually depends on the stage of the disease. Diagnosis and treatment of HCC has witnessed many major changes and challenges in the past years. New alternative lines of treatment of HCC were developed to attack the tumor at the molecular level to improve the prognosis and achieve better results. These include check-point inhibitor therapy, molecular targeted therapy and angiogenesis inhibitors.



[1]  Befeler AS, DI Bisceglie AM. Hepatocellular Carcinoma: Diagnosis and Treatment. Gastroenterology 2002; 122:1609-19.
[2]  Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012; 379(9822):1245-55.
[3]  Nordenstedt H, White DL, El-Serag HB. The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis 2010; 42:S206-S214
[4]  Thomas MB, O’Beirne JP, Furuse J, et al. Systemic therapy for hepatocellular carcinoma: cytotoxic chemotherapy, targeted therapy and immunotherapy. Ann Surg Oncol 2008; 15: 1008-14.
[5]  Hedenstierna M, Nangarhari A, Weiland O, Aleman S. Diabetes and cirrhosis are risk factors for hepatocellular carcinoma after successful treatment of chronic hepatitis C. Clin Infect Dis 2016 Jun 9. pii: ciw362.
Show More References
[6]  Zhang X, Zhang H, Ye L. Effects of hepatitis B virus X protein on the development of liver cancer. J Lab Clin Med 2006; 147(2): 58-66.
[7]  McKillop IH, Moran DM, Jin X, et al. Molecular pathogenesis of hepatocellular carcinoma. J Surg Res 2006; 136(1):125-35.
[8]  Li M, Zhao H, Zhang X, et al. Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. Nat Genet 2011; 43(9):828-9.
[9]  Seeff LB. Introduction: The burden of hepatocellular carcinoma. Gastroenterology 2004; 127(5 Suppl 1):S1-4.
[10]  Alison MR. Liver stem cells: implications for hepatocarcinogenesis. Stem Cell Rev 2005; 1(3):253-60.
[11]  Sherman M, Burak K, Maroun J, et al. Multidisciplinary Canadian Consensus Recommendations for the Management and Treatment of Hepatocellular Carcinoma. Current Oncol 2011; 18: 228-40.
[12]  Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut 2014; 63(5):844-55.
[13]  Johnson PJ. The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma. Chn Liver Dis 2001; 5:145-159.
[14]  Daoudaki M, Fouzas I. Hepatocellular carcinoma. Wien Med Wochenschr 2014; 164 (21-22): 450-5.
[15]  Cillo U, Bassanello M, Vitale A, Grigoletto FA, Burra P, Fagiuoli S, et al. The critical issue of hepatocellular carcinoma prognostic classification: which is the best tool available? J Hepatol 2004; 40:124-31.
[16]  Llovet JM, Fuster J, Bruix J. The Barcelona Approach: Diagnosis, Staging, and Treatment of Hepatocellular Carcinoma. Liver Transplantation 2004; 10(2): S115-S120.
[17]  Subramaniam S, Kelley RK, Venook AP. A review of hepatocellular carcinoma (HCC) staging systems. Chin Clin Oncol 2013; 2(4):33.
[18]  Chan SL, Johnson PJ, Mo F, et al. International validation of the Chinese University Prognostic Index for staging of hepatocellular carcinoma: a joint United Kingdom and Hong Kong study. Chinese Journal of Cancer 2014; 33(10):481-91.
[19]  Ghasemi F, Rostami S, Meshkat Z. Progress in the development of vaccines for hepatitis C virus infection. World Journal of Gastroenterology 2015; 21(42):11984-2002.
[20]  Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-30.
[21]  Iliescu L, Mindrut E, Grasu M, Orban C, Tanase A, Toma L. Management of hepatocellular carcinoma - experience of a single center Chirurgia (Bucur) 2014; 109(2): 204-7.
[22]  Kabel AM, Abd Elmaaboud MA. Cancer: Role of Nutrition, Pathogenesis, Diagnosis and Management. World Journal of Nutrition and Health 2014; 2(4): 48-51.
[23]  Yamamoto J, Okada S, Shimada K, Okusata T, Yamasaki S, Ueno H, Kosuge T. Treatment strategy for small hepatocellular carcinoma: comparison of long-term results after percutaneous ethanol injection therapy and surgical resection. Hepatology 2001; 34: 707-13.
[24]  Facciuto ME, Rochon C, Pandey M, et al. Surgical dilemma: liver resection or liver transplantation for hepatocellular carcinoma and cirrhosis. Intention-to-treat analysis in patients within and outwith Milan criteria. HPB: The Official Journal of the International Hepato Pancreato Biliary Association. 2009; 11(5):398-404.
[25]  Hu KQ. Advances in clinical application of cryoablation therapy for hepatocellular carcinoma and metastatic liver tumor. J Clin Gastroenterol 2014;48(10):830-6.
[26]  Raza A, Sood GK. Hepatocellular carcinoma review: current treatment, and evidence-based medicine. World J Gastroenterol 2014; 20(15):4115-27.
[27]  Lencioni R, Petruzzi P, Crocetti L. Chemoembolization of Hepatocellular Carcinoma. Seminars in Interventional Radiology 2013;30(1):3-11.
[28]  Thandassery RB, Goenka U, Goenka MK. Role of Local Ablative Therapy for Hepatocellular Carcinoma. Journal of Clinical and Experimental Hepatology 2014; 4(Suppl 3):S104-S111.
[29]  Lewandowski RJ, Geschwind JF, Liapi E, Salem R. Transcatheter intraarterial therapies: Rationale and overview. Radiology 2011; 259: 641-57.
[30]  Sacco R, Mismas V, Marceglia S, et al. Transarterial radioembolization for hepatocellular carcinoma: An update and perspectives. World Journal of Gastroenterology 2015; 21(21): 6518-25.
[31]  Shiina S, Tateishi R, Arano T, Uchino K, Enooku K, Nakagawa H, et al. Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Am J Gastroenterol 2012; 107(4): 569-77.
[32]  Sanuki N, Takeda A, Kunieda E. Role of stereotactic body radiation therapy for hepatocellular carcinoma. World Journal of Gastroenterology 2014; 20(12):3100-11.
[33]  Villanueva A, Hernandez-Gea V, Llovet JM. Medical therapies for hepatocellular carcinoma: a critical view of the evidence. Nat Rev Gastroenterol Hepatol 2013; 10(1):34-42.
[34]  Chen Y-Y, Yen H-H, Chou K-C, Wu S-S. Thalidomide-based multidisciplinary treatment for patients with advanced hepatocellular carcinoma: A retrospective analysis. World Journal of Gastroenterology 2012; 18(5):466-71.
[35]  Chen K-W, Ou T-M, Hsu C-W, et al. Current systemic treatment of hepatocellular carcinoma: A review of the literature. World Journal of Hepatology 2015;7(10):1412-20.
[36]  Raza A, Sood GK. Hepatocellular carcinoma review: current treatment, and evidence-based medicine.World J Gastroenterol. 2014;20: 4115-27.
[37]  Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10:25-34.
[38]  Abou-Alfa GK, Johnson P, Knox JJ, Capanu M, Davidenko I, Lacava J, et al. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA 2010; 304:2154-60.
[39]  Prete SD, Montella L, Caraglia M, Maiorino L, Cennamo G, Montesarchio V, et al. Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study. Cancer Chemother Pharmacol. 2010; 66: 837-44.
[40]  Cheng AL, Kang YK, Lin DY, Park JW, Kudo M, Qin S, et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol 2013; 31: 4067-75.
[41]  Cainap C, Qin S, Huang WT, Chung IJ, Pan H, Cheng Y, et al. Phase III trial of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC) J Clin Oncol 2013; 31 Suppl 4:abstr 249.
[42]  Finn RS, Kang YK, Mulcahy M, Polite BN, Lim HY, Walters I, et al. Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2012; 18:2090-8.
[43]  Villanueva A, Minguez B, Forner A, Reig M, Llovet JM. Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. Annu Rev Med 2010; 61: 317-28.
[44]  Song MJ, Bae SH. Newer treatments for advanced hepatocellular carcinoma. Korean J Intern Med 2014; 29(2):149-55.
[45]  Hong Y-P, Li Z-D, Prasoon P, Zhang Q. Immunotherapy for hepatocellular carcinoma: From basic research to clinical use. World Journal of Hepatology 2015; 7(7):980-92.
[46]  Kudo M. Immune Checkpoint Blockade in Hepatocellular Carcinoma. Liver Cancer. 2015; 4(4): 201-7.
[47]  Hong YP, Li ZD, Prasoon P, Zhang Q. Immunotherapy for hepatocellular carcinoma: From basic research to clinical use. World J Hepatol 2015;7(7):980-92.
[48]  Pitt JM, Vétizou M, Daillère R, Roberti MP, Yamazaki T, Routy B, et al. Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors. Immunity 2016; 44(6):1255-69.
[49]  Kuznar W. Nivolumab Makes Headwinds into Liver Cancer. American Health & Drug Benefits 2015; 8 (Spec Issue):19.
Show Less References